Core Research

Ipamorelin vs GHRP-2: Selectivity & Research Differences

Ipamorelin and GHRP-2 are growth-hormone-secretagogue research peptides, but they did not produce identical endocrine-response patterns in the original pharmacology studies. The most useful comparison distinguishes GH release from ACTH, cortisol and prolactin responses and keeps animal, cell and human experiments separate. The studies are not evidence for personal performance, human dosing or an unauthorised use of any Core Research material.

Research Use Only: This is a laboratory pharmacology comparison. No human or veterinary administration or hormone-manipulation instructions are supplied.

What did the original ipamorelin pharmacology study test?

Raun and colleagues (1998) described ipamorelin as a pentapeptide growth-hormone secretagogue and evaluated its behaviour in cell and animal systems. The programme included primary rat pituitary-cell work and experiments in rats and swine, with comparisons against other secretagogues.

The authors observed GH-releasing activity and assessed a broader hormone panel. In the swine selectivity experiments, GHRP-2 and GHRP-6 were associated with increased ACTH and cortisol, while ipamorelin did not increase those hormones beyond the GHRH-comparator response under the conditions tested. The relevant statement is a comparative finding in a specific species and experiment, not “ipamorelin can never affect ACTH or cortisol”.

GH release measured under controlled conditions is not proof of every organism-level outcome. The source paper’s chemical and animal pharmacology does not authenticate a commercial supplier’s sequence, chemical form or lot.

What additional evidence exists for GHRP-2?

Arvat and colleagues (1997)00016-8) examined GHRP-2 and hexarelin in small groups of healthy adults, with measurements that included GH, prolactin, ACTH and cortisol. Their reported results showed endocrine responses beyond GH release under the test conditions. This is human experimental pharmacology for GHRP-2 and its named comparator; it is not a human head-to-head trial against ipamorelin.

That distinction matters. Combining a swine ipamorelin result with a human GHRP-2 result may support a hypothesis about different profiles, but it cannot establish that the same difference is quantitatively reproduced in people under a common protocol. No clinical-use conclusion follows for Core Research material.

Side-by-side evidence with species and endpoint preserved

Question Ipamorelin evidence GHRP-2 evidence What cannot be inferred
GH release Raun et al. observed GH-releasing activity in rat and swine models Raun et al. studied swine responses; Arvat et al. measured human responses That the two are equally potent in an unrelated system
ACTH/cortisol No significant rise beyond comparator in Raun’s tested swine setting Increases described in Raun’s swine comparison and Arvat’s human work That ipamorelin never affects these markers in any species
Prolactin Not established as a directly equivalent human comparator from those studies Arvat et al. reported prolactin responses A controlled human head-to-head ipamorelin comparison
Pharmacokinetics Evaluated in separate animal comparisons Different peptidyl secretagogue handling studied A universal kinetic ratio or exposure recommendation
Commercial RUO material Requires independent product/lot evidence GHRP-2 is used here as a literature comparator Pharmacology papers confirming the content of the Core Research vial

These are different evidence sources, not a meta-analysis or direct common-protocol experiment across all rows. The explicit species labels prevent a stronger clinical inference than the sources warrant.

Do ipamorelin and GHRP-2 work through GHRH receptors?

Both are described within the growth-hormone-secretagogue family and associated with the GHS/ghrelin-receptor context. Their receptor-class question differs from analogues of GHRH such as CJC-1295 No DAC or tesamorelin. Similar downstream GH release does not mean that two ligands engage the same upstream receptor.

This is why a study of a GHRH analogue and a separate GHS study should not be treated as direct evidence that a finished blend has greater activity than either constituent. Co-exposure creates a distinct experimental condition with its own necessary controls.

What about pharmacokinetic differences?

Johansen and colleagues investigated pharmacokinetic properties of ipamorelin and related peptidyl GH secretagogues in animal research. The comparators did not necessarily have matching clearance/excretion behaviour. These data support the general conclusion that equal nominal quantities are not identical experimental exposures across different molecules.

They do not supply a universal elimination half-life for a Core Research vial or establish how any finished cartridge behaves after laboratory handling. Pharmacokinetics, prepared-solution stability and physical product compatibility are different evidence categories.

How to evaluate a new secretagogue paper

Keep these fields together whenever reporting a result:

  1. Exact chemical entity: ipamorelin or which GHRP-2 structural form?
  2. System: isolated pituitary preparation, animal model or human research participants?
  3. Primary endpoint: GH release, ACTH/cortisol, prolactin, receptor activity or disposition?
  4. Comparator: GHRH, another secretagogue, vehicle or a direct matched ipamorelin-versus-GHRP-2 arm?
  5. Timing/conditions: enough detail to interpret the observed hormonal response without turning it into a personal-use schedule?
  6. Limitations: are null findings retained, and does the paper really support the generality being claimed?

A selective endocrine response in one swine model is informative science; calling one compound universally “cleaner”, “safer” or “better for muscle growth” is not a supported research conclusion.

Product identity and related Core Research content

For a supplied Ipamorelin 10mg laboratory material, verify sequence and terminal group, salt/counter-ion where stated, mass assignment, chromatographic result and lot through Batch Documentation. A pharmacology paper is not a product certificate, and the GHRP-2 comparator is a research literature entity, not proof that Core Research stocks it.

The CJC-1295 DAC versus No DAC guide distinguishes GHRH structural strategies. Core Research also lists a CJC-1295 No DAC + Ipamorelin 10mg blend; the blend’s existence does not establish synergy or a shared assay response from unrelated constituent papers.

Research references

  1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. DOI: 10.1530/eje.0.1390552. Rat/pituitary and swine model selectivity measurements.
  2. Arvat E et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man. Peptides, 1997. DOI: 10.1016/S0196-9781(97)00016-800016-8). Human experimental comparator, not ipamorelin versus GHRP-2 trial.
  3. Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues. 1998. PMID: 9879640. Animal pharmacokinetic research.